Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. Academic Article uri icon

Overview

abstract

  • BACKGROUND: A shorter dosing regimen of imiquimod for the treatment of actinic keratosis may be effective, with long-term clinical benefits. OBJECTIVE: Imiquimod in one or two shorter courses of treatment was evaluated. METHODS: Patients with actinic keratosis lesions on the head applied imiquimod or vehicle cream 3x/wk for 4 weeks (course 1). Patients with remaining lesions received another course of treatment. Complete and partial clearance rates were evaluated after course 1, after course 2 (overall), and 1 year later. RESULTS: Complete clearance rates were 26.8% (course 1) and 53.7% (overall). Partial clearance rates were 36.6% (course 1) and 61.0% (overall). One-year follow-up recurrence rates were 39% (imiquimod) and 57% (vehicle). LIMITATIONS: Blinded investigators may have been biased toward patients treated with imiquimod identified by treatment site reactions. CONCLUSION: Imiquimod 3x/wk in one or two courses of treatment appears to be effective for the treatment of actinic keratoses on the head, providing long-term clinical benefits. Some recurrences do occur, so long-term follow-up is recommended.

authors

  • Jorizzo, Joseph L
  • Dinehart, Scott
  • Matheson, Robert
  • Moore, Jeffrey K
  • Ling, Mark
  • Fox, Terry L
  • McRae, Scott
  • Fielder, Sandra
  • Lee, James H

publication date

  • May 18, 2007

Research

keywords

  • Aminoquinolines
  • Facial Dermatoses
  • Keratosis
  • Photosensitivity Disorders
  • Scalp Dermatoses

Identity

Scopus Document Identifier

  • 34447291575

Digital Object Identifier (DOI)

  • 10.1016/j.jaad.2007.01.047

PubMed ID

  • 17512087

Additional Document Info

volume

  • 57

issue

  • 2